AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04073914 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Type 1 Teamwork Program
Description: Psychoeducational web program
Study NCT02347163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
Study NCT00627874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: +3D Lenses
Description: wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
Study NCT00696618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fleet Enema
Description: hyper-osmolar preparation
Study NCT01790737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT01790737 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Study NCT03726671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 25% Cho diet
Description: Subjects will consume meals containing 25% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
Study NCT02076711 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04717401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strain-Counterstrain
Description: Strain-counterstrain will be applied to four muscle which are . Tender point of each muscle will be identified then the muscle will be positioned passively in the most relaxed position which will be held for 90 sec. This procedure will repeated 3 times for each muscle
Study NCT04717401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle Energy Technique
Description: Muscle energy technique will be applied to four muscles which are quadratus Lumborum, iliacus, piriform and erector spinae. Each muscle will be positioned passively in stretched position the patient asked to push against the therapist isometrically while holding breath for 5-10sec. After exhalation, the muscle will be moved into a new barrier. This procedure will repeated 3 times for each muscle
Study NCT03199313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sutezolid
Description: Sutezolid supplied as tablets and matching placebo for oral administration.
Study NCT03199313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Sutezolid placebo
Study NCT00251316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate
Description: 30 mCi of 131I
Study NCT00251316 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
Study NCT04061577 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
Study NCT04061577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: 20 minutes of Cathodal tDCS after +/- before endovascular thrombectomy (EVT)
Study NCT01850719 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Partial Meniscectomy
Description: Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
Study NCT03726671 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50% Cho diet
Description: Subjects will consume meals containing 50% of recommended intake of Choline for 2 weeks. On day 12 of the diet period, subjects will consume 250 mg of Cho in the form of Cho chloride (trimethyl-d9, 9%), Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA), as a bolus.
Study NCT01850719 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.~In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study.
Study NCT03463018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Echinacea angustifolia
Description: 20 mg tablet of Echinacea angustifolia, standardized for echinacoside (not less than 3%) and alkamides (not less than 0.8%)
Study NCT03463018 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet containing matching excipients to the active intervention
Study NCT02801435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Icotinib hydrochloride cream
Description: Topical administration for twice daily
Study NCT02801435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0% Icotinib hydrochloride cream
Description: Topical administration for twice daily
Study NCT02801435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.0% Icotinib hydrochloride cream
Description: Topical administration for twice daily
Study NCT02801435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0% Icotinib hydrochloride cream
Description: Topical administration for twice daily
Study NCT02801435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration for twice daily
Study NCT03945799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: Anlotinib: 12mg QD PO d1-14, 21 days per cycle, 8 cycles.
Study NCT00337428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)
Description: GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
Study NCT00337428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)
Description: GARDASIL™ (quadrivalent human papillomavirus \[types 6, 11, 16, 18\] virus-like particle \[VLP\] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
Study NCT00337428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: REPEVAX™ (Concomitant)
Description: REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
Study NCT00337428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: REPEVAX™ (Non-Concomitant)
Description: REPEVAX™ (diphtheria, tetanus, pertussis \[acellular, component\] and poliomyelitis \[inactivated\] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
Study NCT01961752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Study NCT01961752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + saline
Description: All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Study NCT01961752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + triamcinolone acetonide
Description: All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
Study NCT02060981 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
Study NCT03572972 — intervention group
Intervention type: DRUG
Intervention: Dabigatran
Description: Treatment for NVAF patients
Study NCT03572972 — intervention group
Intervention type: DRUG
Intervention: Rivaroxaban
Description: Treatment for NVAF patients
Study NCT03572972 — intervention group
Intervention type: DRUG
Intervention: warfarin
Description: Treatment for NVAF patients
Study NCT03572972 — intervention group
Intervention type: DRUG
Intervention: Antiplatelets
Description: Treatment for NVAF patients
Study NCT00768118 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule
Study NCT00768118 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: electrophoretic mobility shift assay
Study NCT00768118 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT04492852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polypropylene (PROLENE) sutures
Description: After total knee replacement, the skin closure of the patients in this group will be done using polypropylene (PROLENE) sutures.
Study NCT04492852 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staple Sutures
Description: After total knee replacement, the skin closure of the patients in this group will be done using staple sutures.
Study NCT00696618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tap water enema
Description: hypo-osmolar preparation
Study NCT02450591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study NCT02450591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local Therapies
Description: Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
Study NCT02623023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combigan
Description: brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
Study NCT02623023 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refresh tears
Description: This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
Study NCT00777114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, tositumomab
Description: 1. 0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,~2. 0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~3. 0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,~4. 0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and~5. 1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab.
Study NCT01102517 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: video-assisted thoracoscopic surgery
Description: video-assisted thoracoscopic surgery
Study NCT01102517 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: axillary thoracotomy
Description: axillary thoracotomy lobectomy
Study NCT02403986 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Vital Skinboosters Lidocaine
Study NCT04482257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposome Injection combined with 5-FU/LV
Description: Drug: Irinotecan Liposome Injection 70mg/m2 (CSPC) combined with 5-FU/LV; Drug: Irinotecan Liposome Injection 70mg/m2 (Ipsen, ONIVYDETM) combined with 5-FU/LV;
Study NCT00727428 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluLaval® TF
Description: One IM injection.
Study NCT00566995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZACTIMA (Vandetanib) (ZD6474)
Study NCT00404235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00404235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Study NCT02732756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Sleep Duration
Description: This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
Study NCT02732756 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shortened Sleep Duration
Description: This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
Study NCT03966144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoboHear Device
Description: Delivery of haptic sensations followed by testing to assess the ability to interpret stimuli as sounds and words
Study NCT04851080 — intervention group
Intervention type: DEVICE
Intervention: Heart Rate Variability
Description: Heart rate variability is carried out using the complex of prenosological diagnostics VARICARD 2.51 with the ISCIM 6.2 program is methodically based on the technology of analysis of heart rate variability, it uses the original scientific and theoretical substantiation of HRV indicators, which is based on modern ideas about stress, functional state of the body and assessment of health levels. It is designed to assess the risk of developing diseases in persons who are in states bordering health and disease. A decrease in the adaptive capabilities of the organism is considered as the main risk factor, the results obtained with its help are considered from the point of view of the level of health or stressful effects. It can be successfully used to control the effectiveness of medical intervention. Functionally, the complex is designed to register an electrical signal and form conclusions about the functional state of the body, assess the level of stress and its effect on health.
Study NCT04851080 — intervention group
Intervention type: DEVICE
Intervention: Spirometry
Description: Spirometry is carried out using the device Spirotest USPTs-01, equipped with liquid crystal indicators. It is non-invasive method for measuring air flows and volumes as a function of time using forced maneuvers. It is intended for functional diagnostics of the lungs, namely, indication and measurement of forced vital capacity and forced expiratory volume in the first second.
Study NCT04851080 — intervention group
Intervention type: BEHAVIORAL
Intervention: Testing of psycho-physiological functions using four questionnaires
Description: Research of the behavioral time preferences by Composite Scale of Morningness (CSM, Smith C.S., Reilly C., Midkiff K., 1989). Translation into Russian by Kolomeichuk S., May 2015), of the chronotype by Munich ChronoType Questionnaire (MCTQ, Roenneberg T., Merrow M., LMU München, 2006, 2008. Translation into Russian by Putilov A.A., Danilenko K.V., approved by the authors October 2007, updated 2010), of the seasonal pattern by Seasonal Pattern Assessment Questionnaire (SPAQ, Rosenthal N.E., Genhart M., Sack D.A., Skwerer R.G., Wehr T.A., 1987.Translation into Russian by Putilov A.A., Danilenko K.V., Korneeva N.I. 1988, 2002), of the sleep quality by Pittsburgh Sleep Quality Index (PSQI, Russian edition Semenova E.A., Danilenko K.V., October 2009)
Study NCT02060981 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interview Only
Description: Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
Study NCT02060981 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interview plus decision support tool
Description: Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
Study NCT00696618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normosol-R enema
Description: iso-osmolar preparation
Study NCT00227032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: 300 mg, per day for subjects taking EIAEDs~150 mg, per day for those NOT taking EIAEDs
Study NCT03395353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine Hydrochloride
Description: Administered orally
Study NCT04280913 — intervention group
Intervention type: OTHER
Intervention: retrospective analysis
Description: The investigators retrospectively analyzed the hospitalized patients with COVID-19.
Study NCT02026219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 600mg loading
Study NCT02026219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Ticagrelor 180mg loading
Study NCT02493933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine
Study NCT02511639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus is formulated as tablets of 10 mg strength for oral administration.
Study NCT02511639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
Study NCT02511639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aromatase Inhibitors
Description: Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
Study NCT00028093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a with Ribavirin
Description: Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients \<75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
Study NCT00028093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
Study NCT01260298 — intervention group
Intervention type: DEVICE
Intervention: MC1 Ultrasonic Device
Description: Ultrasonic and zonal massage device.
Study NCT02486588 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Messaging
Description: See detailed study description for overview of the different messaging interventions in this study
Study NCT01507740 — intervention group
Intervention type: DRUG
Intervention: Avastin
Description: Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
Study NCT01507740 — intervention group
Intervention type: DRUG
Intervention: Suntent
Description: Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
Study NCT01507740 — intervention group
Intervention type: DRUG
Intervention: Nexavar
Description: Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
Study NCT03136120 — intervention group
Intervention type: DRUG
Intervention: Ipratropium Bromide
Description: Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
Study NCT03136120 — intervention group
Intervention type: PROCEDURE
Intervention: Flexible Bronchoscopy/Biopsy
Description: After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
Study NCT02317627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KD025